B-cell Acute Lymphoblastic Leukemia Clinical Trials
3 recruiting trials for B-cell Acute Lymphoblastic Leukemia. Eligibility criteria explained in plain English.
TrialFinderData lists 3 B-cell Acute Lymphoblastic Leukemia clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 / Phase 2 is the largest group at 33% (1 studies); the largest phase groups are Phase 1 / Phase 2: 1, Phase 2: 1, Phase 1: 1.
Research is led by Stephan Grupp MD PhD (1), Institute of Hematology & Blood Diseases Hospital, China (1), The First Affiliated Hospital of Soochow University (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s) (biological, 1 trial), followed by Autologous, humanized anti-CD19 CAR T cell therapy (huCART19), Inaticabtagene autoleucel.
Track B-cell Acute Lymphoblastic Leukemia trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Co-administration of CART22-65s and huCART19 for B-ALL
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia...
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or...
Evaluate the safety and efficacy of Inaticabtagene autoleucel combined with autologous hematopoietic stem cell transplantation in adolescents or adults with MRD-positive initial...
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main method potentially curing adult B-ALL, but the high treatment-related mortality (NRM) affects overall...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for B-cell Acute Lymphoblastic Leukemia, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for B-cell Acute Lymphoblastic Leukemia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for B-cell Acute Lymphoblastic Leukemia, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.